Coronary Vasomotor Response After Riociguat Exposure

Withdrawn before enrolling · Phase 2

Conditions studied: Coronary Artery Disease

In brief

The aim of the study is to assess the effects of intracoronary Riociguat on coronary blood flow in subjects with coronary artery disease and to compare this effect with the intracoronary nitroglycerin, a coronary vasodilator widly used to treat patients with coronary artery disease.

Key facts

Study ID

NCT01165931

Run by

Bayer

People needed

0

Starts

2012-05-01

Expected to finish

2013-01-01

Last updated by the study team

2013-10-23

Who can join

Age: 18 and older, up to 90. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients with coronary artery disease

You may not qualify if…

• Patents with coronary artery disease with >/= 70% luminal stenosis by coronary angiography in one of the 3 major epicardial coronary arteries (left anterior descending artery [LAD], left circumflex coronary artery [LCX] or right coronary artery [RCA]) undergoing cardiac catheterization

Where it is running

• Study site — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.